Capital Advisors Inc. OK Purchases 22,583 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Advisors Inc. OK grew its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 8.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 300,589 shares of the company’s stock after purchasing an additional 22,583 shares during the quarter. Capital Advisors Inc. OK owned approximately 0.35% of CRISPR Therapeutics worth $14,122,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRSP. Nordea Investment Management AB increased its stake in shares of CRISPR Therapeutics by 40.8% in the 1st quarter. Nordea Investment Management AB now owns 148,700 shares of the company’s stock worth $10,305,000 after purchasing an additional 43,100 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of CRISPR Therapeutics by 451.3% in the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock worth $2,324,000 after buying an additional 27,915 shares during the period. CWM LLC grew its stake in shares of CRISPR Therapeutics by 11,871.1% during the 2nd quarter. CWM LLC now owns 22,386 shares of the company’s stock valued at $1,209,000 after acquiring an additional 22,199 shares during the period. Granite Bay Wealth Management LLC bought a new position in shares of CRISPR Therapeutics during the 2nd quarter valued at approximately $2,375,000. Finally, Principal Financial Group Inc. purchased a new stake in CRISPR Therapeutics in the 1st quarter worth approximately $2,758,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

CRSP has been the subject of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC decreased their price target on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Chardan Capital dropped their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Royal Bank of Canada decreased their target price on CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Finally, Truist Financial dropped their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $75.19.

CRISPR Therapeutics Trading Up 9.4 %

CRISPR Therapeutics stock opened at $50.76 on Friday. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10. The firm has a 50-day moving average price of $47.15 and a 200-day moving average price of $52.38. The firm has a market capitalization of $4.32 billion, a PE ratio of -15.72 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. During the same period in the previous year, the business earned ($0.98) EPS. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.